-- Company on track to report ELEVATE-44-201 Cohort 1 data in Q2 2026, with Cohort 2 data by end of year -- ...

The FDA has granted accelerated approval to zongertinib (Hernexeos) for the treatment of adults with unresectable or ...

Researchers have advanced DTP3, a first-in-class drug targeting the GADD45β/MKK7 complex, into Phase 2 trials for multiple ...

Bihar govt to engage scientists to curb arsenic concentration in leafy, root vegetables ...

CagriSema achieved 23% weight loss after 84 weeks of treatmentCagriSema 2.4/2.4 mg did not meet the primary endpoint of ...

AB Science says a newly identified blood biomarker may help assess masitinib activity in its ongoing Phase 3 ALS clinical ...

Detailed price information for Ars Pharmaceuticals Inc (SPRY-Q) from The Globe and Mail including charting and trades.

Researchers find long-term exposure to mining pollution is associated with significant cognitive impairment in Peruvian ...

Pivotal Phase 3 global KEPLER study of vedolizumab intravenous (IV) in pediatric patients ages 2 to 17, who had an inadequate ...

The latest report in the Lloyd’s Register FOBAS Fuel Insight series on fuel quality trends highlights some worrisome trends in the second half of 2025. The bi-annual Fuel Insight series leverages the ...

In a placebo-controlled phase 2 trial in Chinese people with overweight or obesity, UBT251 led to a statistically significant mean weight loss of up to 19.7% after 24 weeks UBT251 appeared to have a ...

Sleeping for 7 hours and 18 minutes every night may be the sweet spot for warding off the risk of insulin resistance-the precursor to type 2 diabetes-suggests a large observational study published in ...